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Systematic Reviews ajog.orgNeuraxial analgesia to increase the success rate of
external cephalic version: a systematic review and
meta-analysis of randomized controlled trials
Elena Rita Magro-Malosso, MD; Gabriele Saccone, MD; Mariarosaria Di Tommaso, MD;
Michele Mele, MD; Vincenzo Berghella, MDBACKGROUND: External cephalic version is a medical procedure in which the fetus is externally manipulated to assume the cephalic
presentation. The use of neuraxial analgesia for facilitating the version has been evaluated in several randomized clinical trials, but its
potential effects are still controversial.
OBJECTIVE: The objective of the study was to evaluate the effectiveness of neuraxial analgesia as an intervention to increase the success
rate of external cephalic version.
DATA SOURCES: Searches were performed in electronic databases with the use of a combination of text words related to external cephalic
version and neuraxial analgesia from the inception of each database to January 2016.
STUDY ELIGIBILITY CRITERIA: We included all randomized clinical trials of women, with a gestational age 36 weeks and breech or
transverse fetal presentation, undergoing external cephalic version who were randomized to neuraxial analgesia, including spinal, epidural,
or combined spinal-epidural techniques (ie, intervention group) or to a control group (either intravenous analgesia or no treatment).
STUDY APPRAISAL AND SYNTHESIS METHODS: The primary outcome was the successful external cephalic version. The summary
measures were reported as relative risk or as mean differences with a 95% confidence interval.
TABULATION, INTEGRATION, AND RESULTS: Nine randomized clinical trials (934 women) were included in this review. Women who
received neuraxial analgesia had a significantly higher incidence of successful external cephalic version (58.4% vs 43.1%; relative
risk, 1.44, 95% confidence interval, 1.27e1.64), cephalic presentation in labor (55.1% vs 40.2%; relative risk, 1.37, 95%
confidence interval, 1.08e1.73), and vaginal delivery (54.0% vs 44.6%; relative risk, 1.21, 95% confidence interval, 1.04e1.41)
compared with those who did not. Women who were randomized to the intervention group also had a significantly lower incidence
of cesarean delivery (46.0% vs 55.3%; relative risk, 0.83, 95% confidence interval, 0.71e0.97), maternal discomfort (1.2% vs
9.3%; relative risk, 0.12, 95% confidence interval, 0.02e0.99), and lower pain, assessed by the visual analog scale pain score
(mean difference, e4.52 points, 95% confidence interval, e5.35 to 3.69) compared with the control group. The incidences of
emergency cesarean delivery (1.6% vs 2.5%; relative risk, 0.63, 95% confidence interval, 0.24e1.70), transient bradycardia
(11.8% vs 8.3%; relative risk, 1.42, 95% confidence interval, 0.72e2.80), nonreassuring fetal testing, excluding transient
bradycardia, after external cephalic version (6.9% vs 7.4%; relative risk, 0.93, 95% confidence interval, 0.53e1.64), and abruption
placentae (0.4% vs 0.4%; relative risk, 1.01, 95% confidence interval, 0.06e16.1) were similar.
CONCLUSION: Administration of neuraxial analgesia significantly increases the success rate of external cephalic version among
women with malpresentation at term or late preterm, which then significantly increases the incidence of vaginal delivery.
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FIGURE 1
Flow diagram of studies
identified in the systematic
review
The Prisma template indicates the Preferred
Reporting Item for Systematic Reviews and
Meta-Analyses.
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ajog.org Systematic ReviewsSeveral interventions have been evalu-
ated to try to increase the success
of external cephalic version. Among
these, for example, tocolysis has been
associated with a signiﬁcant increase in
cephalic presentation in labor and
decrease in cesarean delivery.4-6 The use
of neuraxial analgesia has also been eval-
uated in several published randomized
clinical trials7-15 to try to increase the
success of external cephalic version, but
its potential beneﬁts are still controversial.
Materials and Methods
Objective
The aim of this systematic review and
meta-analysis of randomized clinical
trials was to evaluate the effectiveness
of neuraxial analgesia as intervention to
increase the success rate of external ce-
phalic version.
Search strategy
This metaanalysis was performed ac-
cording to a protocol recommended for
systematic review.16 The review protocol
was designed a priori deﬁning methods
for collecting, extracting and analyzing
data. The research was conducted using
MEDLINE, EMBASE, Web of Sciences,
Scopus, ClinicalTrial.gov, OVID, and
Cochrane Library as electronic databases.
The trials were identiﬁed with the use of a
combination of the following text words:
external cephalic version, anesthesia,
analgesia, spinal, epidural, anesthetic in-
terventions, obstetric anesthesia, regional
anesthesia, and randomized from the
inception of each database to January
2016. No restrictions for language or
geographic location were applied.
Study selection
We included all randomized clinical tri-
als of women with breech and/or trans-
verse presentation undergoing external
cephalic version who were randomized
to neuraxial analgesia, including spinal
analgesia, epidural analgesia, or com-
bined spinal-epidural technique (ie,
intervention group) or to intravenous
analgesia or no anesthetic treatment
(control group). We therefore included
both studies comparing neuraxial anal-
gesia vs intravenous analgesia and
studies comparing neuraxial analgesia vsno anesthetic intervention. Only women
with gestational age at or greater than 36
weeks were included. Quasirandomized
trials (ie, trials in which allocation was
done on the basis of a pseudorandom
sequence, eg odd/even hospital number
or date of birth, alternation) were
excluded.
Data extraction and risk of bias
assessment
The risk of bias in each included
study was assessed by using the criteria
outlined in the Cochrane Handbook for
Systematic Reviews of Interventions.16
Seven domains related to risk of bias
were assessed in each included trial
because there is evidence that these issues
are associated with biased estimates of
treatment effect including the following:
(1) random sequence generation; (2)
allocation concealment; (3) blinding of
participants and personnel; (4) blinding
of outcome assessment; (5) incomplete
outcome data; (6) selective reporting;
and (7) other bias. Review authors’
judgments were categorized as low risk,
high risk, or unclear risk of bias.16
All analyses were done using an
intention-to-treat approach, evaluating
women according to the treatment
group to which they were randomly
allocated in the original trials. The pri-
mary outcome was successful external
cephalic version, deﬁned as the per-
centage of fetuses that were externally
rotated from breech or transverse
presentation to a vertex presentation at
external cephalic version.
Secondary outcomes were incidence of
cesarean delivery, vaginal delivery, vaginal
breech delivery, emergency cesarean de-
livery, fetal morbidity (transient brady-
cardia and nonreassuring fetal testing
after external cephalic version), maternal
discomfort, maternal pain score, and
incidence of abruption placentae.
Data from each eligible study
were extracted without modiﬁcation
of original data onto custom-made
data collection forms. Two authors
(E.R.M.-M. and G.S.) independently
assessed inclusion criteria, risk of bias,
and data extraction. Disagreements were
resolved by consensus through a dis-
cussion with a third reviewer (V.B.).SEPTEMBER 2016 AmData not presented in the original pub-
lications were requested from the prin-
cipal investigators.
We planned to assess the primary
outcome (ie, successful external cephalic
version) in subgroup analyses according
to the type of control (either intravenous
analgesia or no anesthetic intervention)
and also according to the type of neu-
raxial technique (spinal vs epidural). We
also performed a sensitivity analysis
according to the risk of bias of the
included trials.
Data analysis
The data analysis was completed
independently by 2 authors (E.R.M.-M.
and G.S.) using Review Manager
5.3 (The Nordic Cochrane Center,erican Journal of Obstetrics& Gynecology 277
FIGURE 2
Assessment of risk of bias
A, Summary of the risk of bias for each trial. The plus sign indicates a low risk of bias; the minus sign indicates a high risk of bias; the question mark
indicates an unclear risk of bias. B, Risk of bias graph about each risk of bias item presented as percentages across all included studies.
Magro-Malosso. Effectiveness of neuraxial anesthesia on external cephalic version. Am J Obstet Gynecol 2016.
Systematic Reviews ajog.orgCochrane Collaboration, 2014; Copen-
hagen, Denmark). The completed ana-
lyses were then compared, and any
difference was resolved with review of
the entire data and independent analysis.
Between-study heterogeneity was
explored using the I2 statistic, which
represents the percentage of between-
study variation that is due to heteroge-
neity rather than chance. A value of 0%
indicates no observed heterogeneity,
whereas I2 values of 50% indicate
a substantial level of heterogeneity.
A ﬁxed-effects model was used if sub-
stantial statistical heterogeneity was not
present. On the contrary, if there was
evidence of signiﬁcant heterogeneity
between studies included, a random-
effect model was used.16 Potential pub-
lication biases were assessed statistically
by using Begg’s and Egger’s tests.16 A
value of P < .05 was considered statisti-
cally signiﬁcant.278 American Journal of Obstetrics& GynecologyTests for funnel plot asymmetry were
carried out only with an exploratory aim
when the total number of publications
included for each outcome was less
than 10. In this case, the power of the tests
is too low to distinguish chance from real
asymmetry. The summary measures were
reported as relative risk or as mean dif-
ferences with 95% conﬁdence interval.
The metaanalysis was reported
following the Preferred Reporting
Item for Systematic Reviews and
Meta-Analyses statement.17 Before data
extraction, the review was registered
with the International Prospective Reg-
ister of Systematic Reviews (registration
number CRD42016036363).
Results
Study selection and study
characteristics
Figure 1 shows the ﬂow diagram
(Preferred Reporting Item for SystematicSEPTEMBER 2016Reviews and Meta-Analyses template) of
information derived from the reviewing
of potentially relevant articles. Nine
randomized clinical trials (934 women),
meeting inclusion criteria, were included
in this review.7-15 Two studies were
published in abstract form only.10,11
Tests for funnel plot asymmetry were
carried out only with an exploratory
aim because the total number of
publications included for each outcome
was less than 10. Despite this, the
quality of the randomized clinical trials
included in our metaanalysis assessed
by the Cochrane Collaboration’s tool
was high.16 All the included studies had
low risk of bias in allocation conceal-
ment, random sequence generation,
and incomplete outcome data. In 3
of the included randomized clinical
trials, all investigators were blinded for
anesthetic intervention to the random-
ization (Figure 2).7,8,15
TABLE 1
Characteristics of the included trials
Characteristics
Schorr et al,
19977
Dugoff et al,
19998
Mancuso et al,
20009
Hollard et al,
200310
Delisle et al,
200311
Weiniger et al,
200712
Sullivan et al,
200913
Weiniger et al,
201014
Khaw et al,
201515
Study location Mississippi Colorado Hawaii California British Columbia Israel Illinois Israel China
Sample size 69 (35/34) 102 (50/52) 108 (54/54) 36 (17/19) 201 (99/102) 70 (36/34) 95 (48/47) 64 (31/33) 189 (63/63/63)a
Type of
malpresentation
Breech 31/35
(88.6%) vs 29/34
(85.3%) transverse
4/35 (11.4%) vs
5/34 (14.7%)
Breech Breech 50/54
(92.6%) vs
49/54 (90.7%)
transverse 4/54
(7.4%) vs 5/54
(9.3%)
Breech Nonvertex Breech Breech Breech Breech
GA at ECV, wks >37 >36 37 >36 >36 37e40 36 37e40 At term
Regional analgesia
(epidural and/or
spinal)
Epidural, 2%,
lidocaine
with 1:200,000
epinephrine
Spinal, 10 mg
sufentanil and
1 mL of 0.25%
bupivacaine
Epidural, 2%
lidocaine with
1:200,000
epinephrine and
100 mg of fentanyl
Spinal, 6 mg of
2% lidocaine
and 15 mg
fentanyl
Spinal, 2.5 mg
bupivacaine and
20 mg fentanyl
Spinal, 7.5 mg
bupivacaine
Spinal: 2.5 mg
bupivacaine and
15 mg fentanyl
Epidural: 45 mg
lidocaine and
15 mg epinephrine
Spinal: 7.5 mg
bupivacaine
Spinal: 9 mg
bupivacaine
and 15 mg
remifentanil
(group 1)
Control group No anesthetic
intervention
No anesthetic
intervention
No anesthetic
intervention
No anesthetic
intervention
No anesthetic
intervention
No anesthetic
intervention
IVA No anesthetic
intervention
IVA (group 2)
No anesthetic
intervention
(group 3)
IVA — — — — — — 50 mg fentanyl — 0.1 mg/kg
remifentanil
Blinded All investigators
were blinded
All investigators
were blinded
Not reported Operators were
not blinded
Not reported The 2 obstetricians
were not blinded
Obstetricians were
not blinded
The two
obstetricians
were not
blinded
Operators
were blinded
Tocolysis 0.25 mg
terbutaline,
SC
0.25 mg
terbutaline i.v.
0.25 mg
terbutaline SC
0.25 mg
terbutaline SC
Nitroglycerin i.v. Ritodrine 50 mg
i.v./ nifedipine
20 mg SLb
0.25mg
Terbutaline i.v.
Ritodrine 50mg
i.v. / nifedipine
20 mg SLb
10 mg
hexoprenaline
i.v.
Hydration before
anesthesia
2000 mL Ringer’s
solution
500 mL Ringer’s
solution
1500 mL Ringer’s
solution
1000 mL
Ringer’s
solution
At the discretion
of the attending
anesthesiologist
1000 mL Ringer’s
solution
500 mL Ringer’s
solution
1000 mL
Ringer’s
solution
500 mL
Hartmann’s
solution
Number of
maximum
attempts
at ECV
3 4 3 2.1  1.4 vs
2.6  1.4c
4 3 Not reported 3 5
Number of
operators
Not reported Not reported 2 1 Not reported 2 Not reported 2 2
Magro-Malosso. Effectiveness of neuraxial anesthesia on external cephalic version. Am J Obstet Gynecol 2016. (continued)
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280 American Journal of Obstetrics& Gynecology SEPTEMBER 2016Publication bias, assessed using Begg’s
and Egger’s tests, was not signiﬁcant
(P ¼ .77 and P ¼ .64, respectively). Sta-
tistical heterogeneity within the trials
was low, with no inconsistency in the
risk estimate for the primary outcome.
Unpublished data were provided by one
author.10
Table 1 shows the characteristics of the
included trials. Table 2 shows inclusion
and exclusion criteria. Characteristics of
the women included (maternal age,
gestational age at external cephalic
version, parity and anterior placenta
location) were reported in Table 3. All
studies randomized women with
singleton breech or transverse pre-
sentations at term or late-preterm (36
weeks) and no contraindications to
external cephalic version.
All randomized clinical trials used
a tocolytic drug in both groups and
hydration before the anesthetic inter-
vention. Tocolytic therapy differed in the
type of agent used and in
route of administration: 3 trials used
subcutaneous terbutaline,7,9,10 2 trials
used intravenous terbutaline,8,13 1 used
intravenous hexoprenaline,15 1 used
intravenous nitroglycerine,11 and 2
studies12,14 used intravenous ritodrine,
which was replaced with sublingual
nifedipine after 8 months because of
nonavailability of this drug during the
study.
One study compared neuraxial
analgesia with intravenous analgesia13;
7 trials compared neuraxial analgesia
with no anesthetic intervention.7-12,14
The trial of Khaw et al15 was a double-
phased, 3-armed randomized blinded
study: in phase I, 189 women were ran-
domized to external cephalic version
under either spinal anesthesia, intrave-
nous analgesia, or no anesthetic in-
terventions (control group); in phase II,
women in the control group in whom
the initial external cephalic version failed
were further randomized to receive
either spinal analgesia (n ¼ 9) or intra-
venous analgesia (n¼ 9) for a reattempt.
We therefore excluded the phase II from
our metaanalysis.
Regarding the intervention, 6 studies
addressed the effect of spinal analgesia
on external cephalic version8,10-12,14,15;
TABLE 2
Inclusion and exclusion criteria of the included trials
Study Inclusion criteria Exclusion criteria
Schorr et al,
19977
GA >37 wks Placenta previa, evidence of fetal compromise, IUGR, PROM
Dugoff et al,
19998
GA 36 wks, breech presentation (not transverse or
oblique lie); reactive NST; intact membranes with a
minimum 2  2 cm pocket of amniotic fluid
Gross fetal anomalies, uterine malformation, EFW >4000 g, IUGR,
placenta previa; known maternal history of third-trimester vaginal
bleeding; labor, no contraindications to spinal anesthesia or
terbutaline
Mancuso et al,
20009
At least 18 y with singleton pregnancies of at least 37
wks in breech or transverse presentations, intact
membranes, EFW between 2000 and 4000 g,
reassuring FHR testing
Placenta previa, prior classical CD, third-trimester bleeding, AFI <5
cm or >25 cm, known uterine malformation, uncontrolled
hypertension, suspected major fetal anomaly, active-phase labor
Hollard et al,
200310
Singleton gestation, breech presentation, GA>36 wks,
not in labor, reactive fetal heart rate
Uteroplacental insufficiency, third-trimester bleeding, IUGR, AFI <6,
uterine malformations, placenta previa, maternal cardiac or
hypertensive disease, PROM, fetal anomaly, EFW >4500 g, previous
uterine surgery, maternal obesity >50% of IBW
Delisle et al,
200311
Singleton fetuses in a nonvertex presentation,
maternal age of at least 18, GA 36 wks, intact
membranes, reactive NST
Not reported in abstract
Weiniger et al,
200712
ASA status I-II, GA 37e40 wks, no fetal abnormality Previous uterine surgery or uterine anomaly, contraindication for
vaginal delivery and for regional analgesia, patient refusal of regional
analgesia, neuropathy, severe back pain with neurological radiation,
poor communication, BMI 40 kg/m2
Sullivan et al,
200913
GA36 wks, singleton pregnancies, willing to receive
either CSE analgesia or systemic opioid analgesia for
ECV
Contraindications to neuraxial anesthesia or allergies to any study
medication
Weiniger et al,
201014
ASA status I-II, GA 37e40 wks, no fetal abnormality
(including IUGR), no contraindication for vaginal
delivery and for regional analgesia
Previous CD, previous myomectomy with uterine cavity penetration or
uterine anomaly, BMI 40 kg/m2, AFI <7 cm, neuropathy, severe
back pain with radicular radiation, request for elective CD
Khaw et al,
201515
ASA status I-II, term parturients, breech-presenting
fetus
Contraindications to ECV including patients with known uterine scar or
anomaly, unexplained third-trimester bleeding, obstetric or medical
conditions complicating pregnancy, compromised fetus, nuchal cord,
fetal anomaly, PROM, labor
AFI, amniotic fluid index; ASA, American Society of Anesthetists, BMI, body mass index; CD, cesarean delivery; CSE, combined spinal-epidural; EC, external cephalic version; ECV, external cephalic
version; EFW, estimated fetal weight; FHR, fetal heart rate; GA, gestational age; IBW, ideal body weight, IUGR, intrauterine growth restriction; NST, nonstress test; PROM, premature rupture of
membranes.
Magro-Malosso. Effectiveness of neuraxial anesthesia on external cephalic version. Am J Obstet Gynecol 2016.
ajog.org Systematic Reviews2 studies assessed the effect of
epidural.7,9 Sullivan et al13 used a com-
bined spinal-epidural technique.
Of the 934 singletons included in
the metaanalysis, 433 (46.4%) were
randomized to the neuraxial analgesia
group (ie, intervention group) and
501 (53.6%) to the control group (either
intravenous analgesia or no anesthetic
intervention).
Synthesis of results
Table 4 shows the pooled data of the
primary and the secondary outcomes of
the metaanalysis. Women who received
neuraxial techniques had a signiﬁcantly
higher incidence of successful externalcephalic version (58.4% vs 43.1%; rela-
tive risk, 1.44, 95% conﬁdence interval,
1.27e1.64) (Figure 3), cephalic presen-
tation in labor (55.1% vs 40.2%; relative
risk, 1.37, 95% conﬁdence interval,
1.08e1.73), and vaginal delivery (54.0%
vs 44.6%; relative risk, 1.21, 95% conﬁ-
dence interval, 1.04e1.41) compared
with those who did not.
Women who were randomized to
the intervention group had also a
signiﬁcantly lower incidence of cesarean
delivery (46.0% vs 55.3%; relative
risk, 0.83, 95% conﬁdence interval,
0.71e0.97), maternal discomfort (1.2%
vs 9.3%; relative risk, 0.12, 95% conﬁ-
dence interval, 0.02e0.99), and lowerSEPTEMBER 2016 Ampain, assessed by the visual analog scale
pain score (mean differences, e4.52
point 95% conﬁdence interval, e5.35
to 3.69) compared with the control
group.
The incidences of emergency
cesarean delivery (1.6% vs 2.5%; relative
risk, 0.63, 95% conﬁdence interval,
0.24e1.70), transient bradycardia
(11.8% vs 8.3%; relative risk, 1.42, 95%
conﬁdence interval, 0.72e2.80), non-
reassuring fetal testing, excluding tran-
sient bradycardia, after external cephalic
version (6.9% vs 7.4%; relative risk, 0.93,
95% conﬁdence interval, 0.53e1.64),
and abruptio placentae (0.4% vs 0.4%;
relative risk, 1.01, 95% conﬁdenceerican Journal of Obstetrics& Gynecology 281
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282 American Journal of Obstetrics& Gynecology SEPTEMBER 2016interval, 0.06e16.1) were not signiﬁ-
cantly different.
Subgroup analysis of the primary
outcome (ie, successful external cephalic
version) concurred with the overall
analysis for the following:
1. Studies in which control was intra-
venous analgesia13: relative risk, 1.54,
95% conﬁdence interval, 1.22e2.63.
2. Studies in which the control was no
anesthetic intervention7-12,14: relative
risk, 1.50, 95% conﬁdence interval,
1.26e1.77.
3. Studies inwhich spinal anesthesiawas
used as neuraxial analgesia8,10-12,14,15:
relative risk, 1.34, 95% conﬁdence
interval, 1.17e1.54.
4. Studies in which epidural analgesia
was used as neuraxial analgesia7,9:
relative risk, 1.91, 95% conﬁdence
interval, 1.36e2.68.
5. The successful external cephalic
version rate was still signiﬁcantly
higher in the neuraxial analgesia
group and also in the sensitivity
analysis of trials with no high risk of
bias items (Figure 2) according to the
Cochrane Risk of bias tools (relative
risk, 1.23, 95% conﬁdence interval,
1.03e1.46).8,15
Moreover, by using an indirect
comparison metaanalysis, we found no
differences in the successful rate of
external cephalic version comparing
spinal analgesia with epidural analgesia
(relative risk, 1.17, 95% conﬁdence
interval, 0.72e1.91).
Comment
Main ﬁndings
This metaanalysis from 9 carefully con-
ducted and low risk of bias randomized
clinical trials, including 934 singleton
pregnancies with malpresentation
(either breech or transverse presenta-
tion) at term or late preterm (36
weeks), showed that the administration
of neuraxial analgesia in addition to a
tocolytic drug signiﬁcantly increased the
success rate of external cephalic version
compared with a tocolytic drug alone.
Pooled results showed a positive effect
of neuraxial analgesia on reducing the
cesarean delivery, maternal discomfort,
TABLE 4
Primary and secondary outcomes
Outcomes
Schorr
et al, 19977
Dugoff
et al, 19998
Mancuso
et al, 20009
Hollard
et al, 200310
Delisle et al,
200311
Weiniger
et al, 200712
Sullivan
et al, 200913
Weiniger
et al, 201014
Khaw
et al,
201515 Total I2
RR or MD
(95% CI)
Successful
ECV
24/35 (68.6%) vs
11/34 (32.3%)
22/50 (44.0%) vs
22/52 (42.3%)
32/54 (59.2%)
vs 18/54
(33.3%)
9/17 (52.9%)
vs 10/19
(52.6%)
41/99 (41.4%)
vs 31/102
(33.7%)
24/36 (66.6%)
vs 11/34
(32.3%)
22/48 (45.8%)
vs 14/47
(30.0%)
27/31 (87.0%)
vs 19/33
(57.6%)
52/63
(82.5%)
vs 80/126
(63.5%)
253/433
(58.4%)
vs 216/501
(43.1%)
16% 1.44
(1.27e1.64)
Cephalic
presentation
in labor
24/35 (68.6%) vs
10/34 (29.4%)
20/50 (40%) vs
26/52 (50%)
32/54 (59.2%)
vs 19/54
(35.2%)
10/17 (58.8%)
vs 9/19
(47.4%)
Not reported Not reported Not reported Not reported Not
reported
86/156
(55.1%)
vs 64/159
(40.2%)
75% 1.37
(1.08e1.73)
Vaginal
delivery
23/35 (65.7%) vs
7/34 (20.6%)
16/50 (32.0%) vs
25/52 (48.1%)
29/54 (53.7%)
vs 17/54
(31.5%)
9/17 (52.9%)
vs 8/19
(42.1%)
Not reported Not reported 17/48 (36.0%)
vs 12/47
(25.0%)
27/31 (87.1%)
vs 30/33
(91.0%)
40/63
(63.5%)
vs 64/126
(51.0%)
161/298
(54.0%)
vs 163/365
(44.6%)
91% 1.21
(1.04e1.41)
Vaginal
breech
delivery
Not reported 0/50 (0.0%) vs
0/52 (0.0%)
1/54 (1.8%)
vs 3/54
(5.5%)
0/17 (0.0%)
vs 0/19
(0.0%)
Not reported Not reported 0/48 (0.0%)
vs 0/47
(0.0%)
0/31 (0.0%)
vs 3/33
(9.1%)
Not
reported
1/102
(0.98%) vs
6/106 (5.6%)
0% 1.17
(0.02e1.41)
CD 12/35 (34.3%) vs
27/34 (79.4%)
34/50 (68.0%) vs
27/52 (51.9%)
25/54 (46.3%)
vs 37/54
(68.5%)
8/17 (47.0%)
vs 11/19
(57.9%)
Not reported Not reported 31/48 (64.0%)
vs 35/47
(75.0%)
4/31 (12.9%)
vs 3/33
(9.1%)
23/63
(36.5%)
vs 62/126
(49.2%)
137/298
(46.0%)
vs 202/365
(55.3%)
75% 0.83
(0.71e0.97)
Emergency
CD within
24 hours
of ECV
Not reported 0/50 (0.0%) vs
1/52 (1.9%)
0/54 (0.0%)
vs 0/54
(0.0%)
1/17 (5.9%)
vs 0/19
(0.0%)
1/73 (1.4%)
vs 0/68
(0.0%)
0/36 (0.0%)
vs 0/34
(0.0%)
1/48 (2.1%)
vs 1/47
(2.1%)
0/31 (0.0%) vs
0/33 (0.0%)
3/63 (4.8%)
vs 9/126
(7.14%)
6/372 (1.6%)
vs 11/433
(2.5%)
0% 0.63
(0.24e1.70)
Transient
bradycardia
Not reported 11/50 (22.0%) vs
6/52 (12.0%)
2/54 (3.7%)
vs 3/54
(5.5%)
3/17 (17.6%)
vs 3/19
(15.8%)
Not reported Not reported Not reported 2/31 (6.4%) vs
1/33 (3.0%)
Not
reported
18/152
(11.8%)
vs 13/156
(8.3%)
45% 1.42
(0.72e2.80)
Nonreassuring
fetal testing
(excluding
transient
bradycardia)
after ECV
Not reported 0/50 (0.0%) vs
1/52 (1.9%)
Not reported 1/17 (5.9%)
vs 0/19
(0.0%)
1/73 (1.4%)
vs 0/68
(0.0%)
2/36 (5.5%)
vs 0/34
(0.0%)
14/48 (29.2%)
vs 13/47
(27.6%)
1/31 (3.0%) vs
0/33 (0.0%)
3/63
(4.8%)
vs 9/126
(7.1%)
22/318
(6.9%)
vs 23/311
(7.4%)
15% 0.93
(0.53e1.64)
Maternal
discomfort
1/35 (2.8%) vs
4/34 (11.8%)
0/50 (0.0%) vs
4/52 (8.0%)
Not reported Lower in RA
group
Not reported Lower in RA
group
Lower in RA
group
Lower in RA
group
Lower
in RA
group
1/85 (1.2%)
vs 8/86
(9.3%)
0% 0.12
(0.02e0.99)
Magro-Malosso. Effectiveness of neuraxial anesthesia on external cephalic version. Am J Obstet Gynecol 2016. (continued)
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284 American Journal of Obstetrics& Gynecology SEPTEMBER 2016and maternal pain and also a positive
effect on increasing the rate of cephalic
presentation in labor and thus the rate of
vaginal delivery. Our metaanalysis rep-
resents level 1 data and included well-
designed and high-quality studies. A
test of heterogeneity and subgroup ana-
lyses all point to the efﬁcacy of neuraxial
analgesia as studies so far.
Comparison with existing literature
In 2015, a Cochrane review analyzed
possible interventions for helping
to turn term breech babies to cephalic
presentation with external cephalic
version.4 The authors found an increase
of the rate of successful external cephalic
version with regional analgesia in
combination with tocolytic therapy
compared with tocolysis alone, but no
difference was identiﬁed in cesarean de-
livery. However this metaanalysis did
not include all currently available ran-
domized clinical trials.
Strengths and limitations
One of the strengths of our study is the
inclusion of only randomized clinical
trial data on external cephalic version
in a speciﬁc population (ie, singleton
gestations at term or near term with
malpresentation). Our metaanalysis
included all studies published so far on
the topic and studies of high quality and
with a low risk of bias according to the
Cochrane risk of bias tools. To our
knowledge, no prior metaanalysis on
this issue is as large, up to date, or
comprehensive. The protocol of this
review was a priori registered on the
International Prospective Register of
Systematic Reviews. Statistical tests
showed no signiﬁcant potential publi-
cation biases. An intent-to-treat anal-
ysis was used, and both random and
mixed-effects models were used when
appropriate. These are key elements
that are needed to evaluate the reli-
ability of a metaanalysis.16 All included
women received tocolytics at external
cephalic version, which should be done,
given their beneﬁt.4
Limitations of our study are inherent
to the limitations of the included ran-
domized clinical trials. The randomized
clinical trials included in this
FIGURE 3
Forest plot for successful of external cephalic version
CI, confidence interval; M-H, Mantel-Haenszel.
Magro-Malosso. Effectiveness of neuraxial anesthesia on external cephalic version. Am J Obstet Gynecol 2016.
ajog.org Systematic Reviewsmetaanalysis were a mix of neuraxial
techniques including epidural, spinal
(usedmost often), and combined spinal-
epidural. These individual techniques
used different local anesthetics types
in varying concentrations and doses.
Opioid types and concentrations
differed as well. In addition, the level of
block obtained was not uniform. All of
these variables may have an impact on
the outcome and the success of external
cephalic version because they can inﬂu-
ence perception of maternal pain,
abdominal and pelvic muscle relaxation,
and anterior abdominal wall muscle
relaxation (possibly altering maternal
guarding that can occur with external
cephalic version and have a negative
impact on its success).
The presence of cotreatments and
different control groups represent
other limitations of this systematic
review. Different types and doses of
neuraxial analgesia were used, making
it unclear which of these should be
preferred. Ideally, spinals and epidurals
should be compared with each other
using uniform drug, opioid type,
concentrations, and analgesic level.
Most of the included studies were not
double blind. This was therefore a
considerable source of bias that may
have affected treatment of these
women or their neonates. In fact, theincidence of successful external ce-
phalic version was slightly lower than
usually reported in the control group
(43.1%).1
Conclusions and implications
Neuraxial analgesia in addition of
tocolytic therapy can be considered a
reasonable intervention to signiﬁcantly
increase external cephalic version suc-
cess rate and cephalic presentation in
labor and thus the incidence of vaginal
delivery, with signiﬁcantly reduced
incidence of cesarean delivery. Neurax-
ial analgesia before external cephalic
version was safe because it was not
associated with increased fetal adverse
events, including transient bradycardia
or other nonreassuring fetal testing,
or abruptio placentae. Women who
received neuraxial analgesia had less
pain and discomfort that those who did
not.
Remaining questions are what type of
neuraxial anesthesia and what type and
dose of anesthetic drug should be used
for external cephalic version.
In summary, the administration
of neuraxial analgesia signiﬁcantly in-
creases the success rate of external ce-
phalic version among women with
malpresentation at term or late preterm,
which then signiﬁcantly increases the
incidence of vaginal delivery. -SEPTEMBER 2016 AmACKNOWLEDGMENTS
We thank Dr Amie Hollard for providing addi-
tional unpublished data from her randomized
clinical trial.10
REFERENCES
1. American College of Obstetricians and Gy-
necologists. ACOG practice patterns. External
cephalic version. Number 4, July 1997. Int J
Gynaecol Obstet 1997;59:73-80.
2. Hannah ME, Hannah WJ, Hewson SA,
Hodnett ED, Saigal S, Willian AR. Planned
caesarean section versus planned vaginal birth
for breech presentation at term: a randomised
multicentre trial. Lancet 2000;356:1375-83.
3. Hutton EK, Hofmeyr GJ, Doeswell T. External
cephalic version for breech presentation before
term. Cochrane Database Syst Rev 2015;7:
CD000084.
4. Cluver C, Gyte GM, Sinclair M, Dowswell T,
Hofmeyr GJ. Interventions for helping to turn
term breech babies to head ﬁrst presentation
when using external cephalic version. Cochrane
Database Syst Rev 2015;2:CD000184.
5. Impey L, Pandit M. Tocolysis for repeat
external cephalic version in breech presentation
at term: a randomized, double-blinded, placebo-
controlled trial. BJOG 2000;112:627-31.
6. American College of Obstetrics and Gyne-
cologists. Committee on Practice Guidelines
Gynecology. External cephalic version. Int J
Gynaecol Obstet 2001;72:198-204.
7. Schorr SJ, Speights SE, Ross EL, et al.
A randomized trial of epidural anesthesia
to improve external cephalic version success.
Am J Obstet Gynecol 1997;177:1133-7.
8. Dugoff L, Stamm CA, Jones OW 3rd,
Mohling SI, Hawkins JL. The effect of spinal
anesthesia on the success rate of externalerican Journal of Obstetrics& Gynecology 285
Systematic Reviews ajog.orgcephalic version: a randomized trial. Obstet
Gynecol 1999;93:345-9.
9. Mancuso KM, Yancey MK, Murphy JA,
Markenson GR. Epidural analgesia for cephalic
version: a randomized trial. Obstet Gynecol
2000;95:648-51.
10. Hollard A, Lyons C, Rumney P, Hunter M,
Reed E, Nageotte M. The effect of intrathecal
anesthesia on the success of external cephalic
version (ECV). Am J Obstet Gynecol 2003;
189(Suppl 1):S140 [abstract].
11. Delisle MF, Kamani AA, Douglas MJ,
Bebbington MW. Antepartum external cephalic
version under spinal anesthesia: a randomized
controlled study. J Obstet Gynaecol Can 2003;
25:S13 [abstract].286 American Journal of Obstetrics& Gynecology12. Weiniger CF, Ginosar Y, Elchalal U,
Sharon E, Nokrian M, Ezra Y. External cephalic
version for breech presentation with or without
spinal analgesia in nulliparous women at term: a
randomized controlled trial. Obstet Gynecol
2007;110:1343-50.
13. Sullivan JT, Grobman WA, Bauuchat JR,
et al. A randomized controlled trial of the effect of
combined spinal-epidural analgesia on the suc-
cess of external cephalic version for breech pre-
sentation. Int J Obstet Anesth 2009;18:328-34.
14. Weiniger CF, Ginosar Y, Elchalal U, Sela HY,
Weissman C, Ezra Y. Randomized controlled
trial of external cephalic version in term multi-
parae with or without spinal analgesia. Br J
Anaesth 2010;104:613-8.SEPTEMBER 201615. Khaw KS, Lee SW, Ngan Kee WD, et al.
Randomized trial of anaesthetic interventions
in external cephalic version for breech
presentation. Br J Anaesth 2015;114:
944-50.
16. Higgins JPT, Altman DG, Sterne JAC.
Cochrane handbook for systematic reviews of
interventions, version 5.1.0 (update March
2011). The Cochrane Collaboration, 2011.
Available at: www.cochrane-handbook.org.
Accessed Dec. 20, 2015.
17. Moher D, Liberati A, Tetzlaff J, Altman DG.
Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA
statement. J Clin Epidemiol 2009;62:
1006-12.
